Scilex Holding Co - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SCLX Nasdaq 2834 https://www.scilexholding.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Scilex Holding Co

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses - Apr 16th, 2024 1:00 pm
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool - Apr 9th, 2024 1:00 pm
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend - Mar 27th, 2024 1:00 pm
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients - Mar 21st, 2024 1:30 pm
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed - Mar 20th, 2024 3:00 pm
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba® - Mar 20th, 2024 1:00 pm
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation - Mar 19th, 2024 1:00 pm
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada - Mar 18th, 2024 1:00 pm
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc. - Mar 15th, 2024 6:45 pm
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement - Mar 15th, 2024 1:00 pm
Scilex Holding Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags - Mar 14th, 2024 11:23 am
SCLX Grows Revenue and Boosts Marketing - Mar 12th, 2024 5:05 pm
Scilex Holding Company (NASDAQ:SCLX) most popular amongst private companies who own 57% of the shares, institutions hold 25% - Mar 9th, 2024 12:21 pm
Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering - Mar 5th, 2024 9:01 pm
Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024 - Mar 5th, 2024 2:00 pm
SCLX Continues to Make Strides - Mar 5th, 2024 11:30 am
Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates - Mar 4th, 2024 2:00 pm
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024 - Mar 2nd, 2024 8:25 pm
Scilex Holding Company Announces $10 Million Bought Deal Offering - Feb 29th, 2024 10:32 pm
Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA® in Most of Their Stores Throughout the U.S. - Feb 28th, 2024 2:00 pm